List of Vendor Companies in Sweden - 59

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Acarix is a Swedish medical device company that innovates solutions for rapid Coronary Artery Disease (CAD) rule-out. The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System rapidly calculates a patient-specific CAD-score non-invasively with 96% confidence. Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

We, at Akira Science - a Stockholm based tech start-up-, use the latest manufacturing technologies to provide you with pliable scaffolds for soft tissue engineering. Our solutions results from the synergistic combination of degradable polymers synthesis expertise, mechanical simulation approach to develop suitable scaffold design to tailor the biological response.

Amferia AB is a Swedish company that develops and markets new medical devices with emphasis on antibacterial products. The core focus of Amferia is to develop materials that can efficiently kill bacteria when used as medical devices, for example within wound care. Amferia is a spin-off from research performed at Chalmers University of Technology. The company was founded in 2018 and the founders of Amferia are Dr. Anand Kumar Rajasekharan, Professor Martin Andersson and Dr. Saba Atefyekta.

ArgusEye provides innovative sensor systems based on nanoplasmonic detection for real-time monitoring of biological systems and processes.

AroCell AB is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser.

BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products within the areas of gut, oral, immune and bone health. Our probiotic products with bacterial strains from the L. reuteri species are among the most scientifically well-documented probiotics. The class B share of BioGaia is quoted on the Mid Cap list of the Nordic Exchange Stockholm.

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina's laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer's efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

Bionamic was founded by researchers to address the frustrating challenge of implementing digitalization in biopharma R&D. Our software platform can serve as a single source of truth for all your antibody related discovery and development data and offers an easy way to navigate it. We have put an incredible amount of thought and effort into making sure the data can be represented in a way that makes sense and helps to solve real problems.

About Biotage Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers' workflows and improving their outcomes. Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT).

Biovica develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and predict patient outcomes. The company’s DiviTum™ TKa assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

BONESUPPORT AB is a Scandinavian orthobiologics company based in Lund, Sweden, specializing in advanced bone graft solutions. Founded in 1999, the company develops and commercializes bioceramic products aimed at managing bone injuries. Its flagship product, CERAMENT®, is an injectable bioceramic material designed for bone void filling and infection management, featuring osteoconductive properties and drug-eluting capabilities for localized antibiotic delivery. The company operates globally, achieving net sales of SEK 899 million in 2024, with significant growth in both North America and Europe. BONESUPPORT focuses on direct commercialization in key markets and partnerships for global distribution. The leadership team includes experienced executives in business administration and orthobiologics, with a strong emphasis on clinical validation and innovative solutions for orthopedic surgeons, trauma centers, and hospitals.

Carbiotix is an award-winning biotechnology company pioneering the onsite upcycling of plant-based side-streams. Carbiotix mission is to improve the health of people by increasing the consumption of prebiotics and other active ingredients from upcycled side-streams. Carbiotix offers one core service today called NutraCycle, an on-site upcycling and fortification service allowing food & beverage, ingredient, and feed producers to turn plant-based products into healthier, more profitable, and sustainable products.

At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We've been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm. Visit elekta.com to learn more.

Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution. EnginZyme is recognised as a Technology Pioneer by World Economic Forum and backed by Sofinnova Partners, Industrifonden, SEB Greentech VC, Bunge Ventures, Almi Invest GreenTech Fund, and Navigare Ventures.

EQL Pharma AB (publ) is a pharmaceuticals company based out of Skåne County, Sweden.

Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™

Gradientech is a Swedish in vitro diagnostics company that supports the modern microbiology lab with cutting-edge solutions to facilitate the workflow with time-critical samples. Our product, QuickMIC®, is an ultra-rapid system for antibiotic susceptibility testing (AST) of positive blood culture samples from sepsis patients. QuickMIC® is a scalable system with each instrument analysing one sample against a tailored gram-negative antibiotic panel. MIC values are reported in as short as 2 hours, making it more rapid than any other diagnostic system for phenotypic AST. Gradientech's technology combines microfluidics with live imaging to analyse bacterial responses on a linear antibiotic concentration gradient. The revolutionary technology delivers MIC values with unprecedented precision in record time.

Gyros Protein Technologies provides enabling peptide synthesis and bioanalytical solutions helping scientists increase biomolecule performance and productivity in pre-clinical/clinical development and bioprocess applications. The automat

Iconovo is a leading Swedish CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. We have several types of patented dry powder inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicine. Our strength is our inhouse capabilities with full control over both device development and formulation, meaning less risk and faster time to market.

ImmunoIVD focuses on molecular assays for neonatal screening. The SPOT-it™ kit is CE marked and has been developed to facilitate population-scale screening to detect newborns with SCID, XLA and/or SMA. The company is built on a strong foundation with more than 30 years experience of successfully running a biotech company, and world renowned researchers within the field of clinical immunology and immunogenetics. Early detection increases the chances for children born with SCID, XLA and SMA to live life to its fullest. We believe all children should be given that chance.

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

We focus on development, modification and production of custom antibodies, as well as their antigens; typically synthetic peptides and recombinant proteins. With more than two decades of experience of delivering products and services in the field of molecular biology, we have a complete toolbox of taking a project from idea to finished antibody – and beyond.

Life Genomics is a private genetic laboratory which was founded in 2014 through the spin-off from TATAA Biocenter AB, to develop offers of genetic tests to the healthcare industry and the public. Life Genomics have two tests on the market: Non-invasive prenatal tests (NIPT) and PCR-test for Covid-19. Further tests are under development.

We are a Swedish company developing immunoassays for life science research. Our goal is to aid research by providing the scientific community with innovative tools, in particular for ELISpot, FluoroSpot, and ELISA. To that end, we develop and produce a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications. We started off in Stockholm in 1986, and our headquarters still lies in Nacka Strand, just east of the inner city. We do everything here, from research and production to finance, IT, quality control, marketing, distribution, and sales. In addition, we have a sales office in Cincinnati, Ohio, and collaborate with great distributors around the globe. The quality of our products really comes down to our entire organization; the balance between individual action and care for the collective. Because for us, quality isn't just a word. It's a mindset, a mantra, and a lens we hold to all our initiatives, whatever the size. As part of the scientific community, we want to do our share to help science progress. So we hope you see us as peers – feel free to strike up any sort of conversation with us.

Moleculent is a biotechnology research company that focuses on mapping and analyzing cell-cell interactions and communication directly within their tissue environment. The company's platform allows for the detection of healthy cell function and the analysis of functional proteins, including receptors and ligands.

Nanexa AB is a drug delivery company that focuses on the development of PharmaShell®, a new and pioneering drug delivery system that is considered to have great potential in a number of substance types and indication areas. Within the framework of PharmaShell®, Nanexa develops its own projects and has collaborative agreements with several pharmaceutical companies, including AstraZeneca.

Navinci is a Swedish biotech company that specializes in developing innovative solutions for the study of protein interactions. With a focus and a strong legacy in the development of in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth. Our Naveni Proximity Ligation Technology is at the forefront of innovation within the field of spatial proteomics and allows for the detection and quantification of protein interactions and post-translational modifications in a manner that is both sensitive and specific. It provides researchers with a valuable tool for their studies and helps deepen the understanding of the interplay between proteins in their native environment. Our latest focus is on target-specific kits within immuno-oncology, which detect interactions such as PD1/PD-L1. These kits are designed to help researchers easily visualize the interactions between immune checkpoint proteins in immune and cancer cells and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. By providing researchers with reliable and innovative tools for visualizing and interpreting protein interplay, Navinci pushes forward the understanding of cell biology and brings precision to spatial proteomics.

NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma's first product, ProTrans,has started in Novermber 2018. #nextcellpharma #cellaviva

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base. For more information visit www.olink.com

Pelago Bioscience AB is founded to accelerate the use and value of the CETSA® technology in Drug Discovery and diagnostics. We know that the need for Target Engagement studies is large and increasing and there is no single technology with the same opportunities to fill this need as CETSA®. We will: - Make more relevant data available to our customers at an earlier stage of the Drug Discovery process - Enable filtering of compounds based on physiologically relevant data to facilitate better decisions in Drug Discovery programs - Provide our customers with CETSA® based Target Engagement data in vitro and in vivo - Improve translation from laboratory to patient by using a single technology - CETSA® - Facilitate development of novel medicine in clinical trials using CETSA® - Develop diagnostic kits, companion diagnostics and tools for monitoring Target Engagement during patient treatment using CETSA® Pelago Bioscience AB will by these accomplishments add value to Drug Discovery programs allowing for faster and better development of new and improved drugs. By developing the CETSA® technology for general clinical use as a diagnostic and treatment monitoring tool we aspire to improve the lives and health of patients.

We are on a mission to build a comprehensive product portfolio dedicated to women's intimate health. Our approach is rooted in the ability to diagnose, treat, and prevent concerns, blending science with aesthetically appealing and beautiful products. We firmly believe women's intimate care should be grounded in scientific exploration. This commitment to research ensures that our products are effective and backed by a robust foundation of research and knowledge. Join us on a movement to redefine women's intimate health.

Perimed AB is a Swedish company, founded in 1981 and headquartered just outside Stockholm. Perimed develops, manufactures and markets state-of-the-art diagnostic equipment to assess microcirculation and peripheral perfusion as well as Peripheral Arterial Disease. We offer solutions for clinical use as well as for research. We have more than 40 years of experience and unique competence in fiber optics, laser and camera optics, as well as tissue optics making Perimed a leader in measuring and assessing microcirculation and peripheral macro circulation. Perimed is a global company with subsidiaries in USA, China, France, Italy and Germany. Our customers in the other countries are supported either directly from our Swedish headquarters or by our certified local distributors listed on our contacts pages.

Phase Holographic Imaging is a company that specializes in live cell imaging and analysis systems, enabling label-free kinetic live cell studies during physiologically optimal conditions. They also provide time-lapse cytometers for long-term imaging and analysis of cell cultures using a patented method that allows living cells to be studied without the use of labels or dyes.

Single cell spatial proteomics. Molecular Pixelation uses DNA-conjugated antibodies and DNA encoded pixels to identify and spatially locate cell surface proteins.

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally.

Qlife is a Danish medical technology company that develops an innovative medical technology platform with the long-term goal of giving people access to safe and validated blood biomarker data at home. The platform called Egoo.health consists of a small diagnostic device with individual capsules containing each a specific biomarker test that can be measured by a single drop of blood from the fingertip.

Qlucore makes it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. It is done by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. The easy to use tools empowers researchers, technicians and physicians to easily interpret and explore their datasets.

Developing state-of-the-art AAV vectors for gene therapy

Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

ADVANCING CANCER TREATMENT RaySearch is advancing cancer treatment through pioneering software. Software has unlimited potential, and we believe it is now the driving force for innovation in oncology. Medical science never stands still, and neither does RaySearch. We work in close cooperation with leading cancer centers to bring scientific advancements faster to the clinical world. Today, our solutions support thousands of clinics worldwide in the fight against cancer. And this is just the beginning.

Recipharm is a leading global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how, and customer connectivity. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of 5 200 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. Since our inception in 1995, we have supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

SARomics Biostructures provides a broad range of structural biology and drug discovery services that include: X-ray crystallography services: Protein cloning, expression, characterization, and crystallization, FastLane™ Standard and FastLane™ Premium off-the-shelf structures, gene-to-structure services. Protein NMR spectroscopy: Peptide NMR & protein NMR assignment, peptide NMR & protein NMR structure determination, protein-ligand & protein-protein complex structure determination, fragment screening using 1D or 2D NMR spectroscopy, epitope mapping and dissociation constant (Kd) determinations for compounds, biosimilars higher order structure (HOS) verification & comparability analysis, formulation characterization and optimization, expression and purification of 2H, 15N, and 13C-labelled protein in E.coli for NMR spectroscopy studies and structure determination. Structure-based lead discovery services: Fragment screening and fragment-based drug design, computational chemistry, in silico drug discovery services. Our integrated drug discovery platform relies on our unique and proprietary weak affinity chromatography screening technology (WAC™). Antibody & antibody-antigen 3D structure determination, higher order structure (HOS) comparability analysis of biosimilars. Why choose SARomics Biostructures The commitments of our highly experienced and competent team of crystallographers, modelers, and molecular biologists include: Swift replies to all contact requests. After the initial project discussion, we provide realistic project timelines. We guarantee high quality services. We have a high degree of customer satisfaction. Our robust technology platform is built around a wide variety of experimental methods required in modern structural biology. We use a unique and verified proprietary method for compound screening. We benefit from an excellent location in Medicon Village in Lund and proximity to one of the world's best synchrotrons, MAX IV.

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com

Senzime is a leading global medical device company, developing precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Our cutting-edge solutions TetraGraph and ExSpiron 2Xi are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory functions during and after surgery. With our dedicated team and strong partnerships, we are on a global mission to safeguard every patient's journey, from anesthesia to recovery. Established in 1999, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). #senzime #tetragraph #patientsafety #tofmonitoring #anesthesia

Introducing next-generation RNase inhibitors - ideal for single-cell and in situ RNA-sequencing SEQURNA's RNase inhibitor makes RNA work and sequencing pipelines more accessible, affordable, and sustainable. Unlike competitors’ recombinant RNase inhibitors, the SEQURNA inhibitor is thermostable and can be shipped and stored at room temperature without affecting performance. These features do not only simplify shipping and storage logistics, eliminate batch effects, and reduce costs for the user – but also enable new and simplified workflows as well as novel laboratory protocols including heat cycles. Propel your biotech business or research, and choose a more environmentally sustainable option for RNase inhibition in your RNA-seq workflows, by becoming an early user of SEQURNA’s RNase inhibitor. Our R&D team is keen to assist and advice in the transition. Find out more at www.sequrna.com or email us at info@sequrna.com

We develop technologies for ultrasensitive analysis of complex DNA sources. Compared to other technologies for ultrasensitive sequencing, our solutions are both simple to use and specifically adapted for analysis of difficult to analyze DNA such as circulating tumor DNA, a biomarker specific for cancer.

SINGLE TECHNOLOGIES develops a new type of single molecule sensitive 3D sequencing system.

Spiber Technologies uses recombinant technology for producing advanced biomaterials. Our primary goal is to develop and commercialize state-of-the-art patented technologies based on the recombinant spider silk protein Spiber™ and the solubility tag SolvNT™ Spiber™-based products can be used as 3D scaffold for culturing stem cells and creating future Regenerative Medicine applications. SolvNT™ can increase solubility for recombinant production of peptides and proteins. The company was founded in 2008. The technologies are based on the successful research on spider silk conducted at the Swedish University of Agricultural Sciences (SLU), the Royal Institute of Technology (KTH) and Karolinska Institutet (KI). The company is privately owned and located in Stockholm, Sweden.

For customers working in the life sciences and pharma industry, Svar offers a unique combination of scientific expertise, high-quality assay products, strong services, and proprietary technology platforms that provide a flexible, effective, and seamless experience for customers through different development needs in a way that no other single business can. At Svar, we are dedicated to our customers' development journey. We harness a deep understanding and long-standing experience in immunological areas such as complement system activation and immunogenicity. We utilize this in our expert cell engineering, assay development, and contract research services capabilities. Our specialist knowledge allows us to help you tackle complex problems, safely and efficiently moving your candidates through the drug development phases and to the patient—also when standard solutions fall short.

Cell metabolism and monitoring made easy - label-free and continuous measurements of biological activity. Multi-channel assay that measures the specific metabolic phenotype for cells and pathogens in real-time with exceptional precision. Return to phenotype - The calScreener™ cell-based assay provides a phenotype response measurement with unprecedented sensitivity and versatility. We enable: Smarter drug development - Bridge the gap between in-vitro and in-vivo testing Rapid and accurate diagnostic - Customize treatments for infections due to multi-resistant bacteria Want to see what others cannot? All living cells produce heat during metabolism. We measure this heat at unsurpassed precision. No heat equals no metabolism. The only absolute measurement of death. We make it possible to see what was previously impossible. Applications are limited only by the imagination of the scientist. Bacteria. Cells. Organoids. Worms. Ants. Feces. If it fits in the tube we can measure it. Symcel is a biotechnology company located in Stockholm and was founded by Dr. Dan Hallen and Prof. Ingemar Wadsö in 2004, leading authorities in the field of biocalorimetry.

At TATAA Biocenter, we offer PCR bioanalytical services to address the challenges in nucleic acid therapy drug development. Our mission as a CRO is to provide assay development, validation, and high-throughput analyses with high sensitivity for regulated and non-regulated bioanalysis, clinical biomarkers, and manufacturing quality assessments to accelerate your time-to-market. As your extended workbench of specialists and dedicated partner, we prioritize quality, innovation, and building strong client relationships. We are a GLP-accredited, GCLP-compliant, and ISO/IEC 17025-certified laboratory. Our purpose-built facility for nucleic acid analyses enhances sensitivity and minimizes contamination risks. With state-of-the-art instrumentation and an IT structure ensuring the highest data integrity and sample management, our collaborative and highly skilled scientists deliver advanced competence and precise execution.

VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company's unique technology platform turns donated allogeneic ("foreign") tissue into an autologous-like ("personalized") tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT's development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.

At Viedoc, we design engaging software that modernizes clinical research so that necessary treatments can reach the people who need them faster. We believe in life and science, in people, and in our collective power to change the world and build a healthier future. That unmatched driving force is what pushes us to innovate, accelerate and improve every aspect of modern clinical studies. Since 2003, Viedoc has united scientists and clinical trial professionals in a shared mission of pushing life-changing research forward. Our solution has been used to power thousands of studies, by collecting data from over a million patients and allowing it to flow smoothly across sites and countries. We take great pride in helping bridge the gap between patient and researcher – and, in the best of cases, between research and breakthrough.

Single-cell and Bulk RNA-sequencing services.

Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients' quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval and has received orphan drug status in the US. Xspray Pharma's management team has extensive experience from the pharmaceutical industry. The company is based in Stockholm and shares are traded on Nasdaq Stockholm. www.xspraypharma.com

Ziccum is developing new dry-powder versions of the world’s most urgently-needed vaccines. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.